Lutathera Disease Interactions

Lutetium Lu 177 dotatate does not undergo hepatic metabolism. No dose adjustment is recommended for patients with mild or moderate hepatic impairment. Care is recommended when using lutetium Lu 177 dotatate in patients with severe hepatic impairment (total bilirubin > 3 times upper limit of normal and any AST) as its safety has not been studied in these patients. Monitor transaminases, bilirubin and serum albumin during treatment.

The use of lutetium Lu 177 dotatate may increase the risk of developing myelosuppression. Care should be exercised when using this agent in immunocompromised patients. It is recommended to monitor blood cell counts. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.

Lutetium Lu 177 dotatate predominantly undergoes renal excretion. No dose adjustment is recommended for patients with mild to moderate renal impairment. It is recommended to assess renal function frequently in patients with mild to moderate impairment during therapy with this agent. . Monitor serum creatinine and calculated creatinine clearance. The safety of lutetium Lu 177 dotatate in patients with severe renal impairment or end-stage renal disease has not been studied